Nakamura, Tomonori

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医療薬学・社会連携センター 医療薬学部門 (Shiba-Kyoritsu)

Position

Professor

External Links

Career 【 Display / hide

  • 1993.04
    -
    1997.03

    Faculty of Pharmaceutical Sicences, Chiba University, Laboratory of Natural Products Chemistry, Reasearch Assistant

  • 1997.04
    -
    1997.06

    Faculty of Pharmaceutical Sciences, Chiba University, Laboratory of Natural Products Chemistry, Research Associate

  • 1997.07
    -
    1999.03

    Center for Basic Sciences, Kitasato Institute, 微生物薬品化学研究室, Post Doctral Fellow (JSPS PosDoc Fellow)

  • 1999.04
    -
    2005.03

    Chiba University Graduate School of Pharmaceutical Sciences, Department of Clinical Pharmacology & Pharmacotherapeutics, Assitant Professor

  • 2005.04
    -
    2007.03

    Chiba University Graduate School of Pharmaceutical Sciences, Department of Clinical Pharmacology & Pharmacotherapeutics, Associate Professor

display all >>

Academic Background 【 Display / hide

  • 1985.04
    -
    1989.03

    Nihon University, Faculty of Science and Engineering, School of Pharmacy

    University, Graduated

  • 1989.04
    -
    1991.03

    Chiba University, Graduate School of Pharmaceutical Sciences, Department of Natural Products

    Graduate School, Completed, Master's course

  • 1991.04
    -
    1993.03

    Chiba University, Graduate School of Pharmaceutical Sciences, Department of Natural Products

    Graduate School, Withdrawal before completion, Doctoral course

Academic Degrees 【 Display / hide

  • Ph.D. in Pharmaceutical Sciences, Chiba University, Dissertation, 1997.05

    和漢薬・民間伝承薬由来の向神経活性成分に関する化学的・薬理学的研究

Licenses and Qualifications 【 Display / hide

  • Pharmacist, 1989.09

  • 日本医療薬学会指導薬剤師, 2007.01

  • 日本臨床薬理学会指導薬剤師, 2018.10

  • 日本医療薬学会認定薬剤師, 2005.01

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy (Clinical Pharmaceutical Science)

Research Keywords 【 Display / hide

  • personalized drug therapy

  • molecular diabetology

  • education of clinical pharmacy

  • kampo medicine/herbal medicine

  • clinical pharmacology

Research Themes 【 Display / hide

  • 和漢薬・生薬の適正使用の推進と薬効薬理メカニズムの解析, 

    2013.04
    -
    Present

  • 医療薬学に関連した薬学教育の洗練化, 

    2013.04
    -
    Present

  • 薬剤抵抗性の発現機構解明と薬動力学解析に基づく個別化薬物治療法の構築, 

    2013.04
    -
    Present

 

Books 【 Display / hide

  • フィジカルアセスメントに基づく症例解析と薬物治療

    大林恭子、中村智徳 編著, 京都廣川書店, 2021.08

  • 今日のOTC薬 改訂第5版

    伊東明彦、中村智徳 編, 南江堂, 2021.02

  • 現代医療における漢方薬 改訂第3版

    NAKAMURA Tomonori, 南江堂, 2020.02,  Page: 175

    Scope: 第7章 漢方薬の服薬指導,  Contact page: 121-135

  • NEO 薬学シリーズ12 早期臨床体験テキスト

    NAKAMURA Tomonori, ネオメディカル, 2017.03

    Scope: 第10章 調剤の基礎を体験する

  • 現代医療における漢方薬 改訂第2版

    NAKAMURA Tomonori, 南江堂, 2016.01

    Scope: 第7章 漢方薬の服薬指導

display all >>

Papers 【 Display / hide

  • Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E)

    Namiki T., Yokoyama Y., Hashi H., Oda R., Jibiki A., Kawazoe H., Matsumoto K., Suzuki S., Nakamura T.

    Pharmacotherapy (Pharmacotherapy)  44 ( 2 ) 149 - 162 2024.02

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  02770008

     View Summary

    Study Objective: Establish methods for measuring cefmetazole (CMZ) concentrations conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations for extended-spectrum β-lactamase producing enterobacterales (ESBL-E) and investigate optimal dosing regimens for not undergoing hemodialysis (non-HD) and undergoing hemodialysis (HD) patients. Design: Prospective observational study. Patients: Included patients treated with CMZ who provided written informed consent and were admitted to the Tokyo Bay Urayasu Ichikawa Medical Center between August 2021 and July 2022. Measurements: Total and Unbound CMZ concentration was measured by high-performance liquid chromatography (HPLC) with solid-phase extraction and ultrafiltration. Setting: Determining the CMZ dosing regimen involved modified creatinine clearance (CLCR) with measured body weight (BW) using the Cockcroft–Gault equation. For non-HD patients, blood samples were collected during at least three points. For patients undergoing HD, 1 g was administered via intravenous infusion, or rapid intravenous injection after HD, or 30 min before the end of HD. Blood samples were collected before HD (pre-HD), and 1 and 3 h after starting HD and post-HD. All blood samples were collected at steady-state. Patient information was collected from electronic medical records. An unbound PK model was constructed for the non-HD patients. A nomogram was constructed using Monte Carlo simulations with a 90% probability of target attainment at 70% free time above the minimum inhibitory concentration (MIC). For the HD patients, a nomogram was used to determine the optimal dosing regimen for each HD schedule. Main Results: CMZ measurement methods were established. A model analysis of unbound PK in 37 non-HD patients incorporated creatinine clearance (CLCR) using the Cockcroft–Gault equation, albumin (ALB) for clearance and body weight (BW) for the volume of distribution. In Monte Carlo simulations, nomograms corresponding to the MIC (known and unknown) were generated for each covariate. Using the nomogram, non-HD patients with an ESBL-E MIC of 8 mg/L, a BW of 60 kg, an ALB of 25 g/L, and a CLCR of 60 mL/min required administration of 2 g every 6 h (1- and 3-h infusions). Unbound PK model parameters were calculated for 7 HD patients, and the optimal dosing regimens following PK/PD were determined for each HD schedule. In HD patients, the regimen after and during HD was established using a treatment that was effective up to an ESBL-E MIC of 4 mg/L. Conclusions: The nomogram for CMZ regimens established by PK/PD analysis of measured CMZ concentrations enables optimal CMZ dosing for ESBL-E-infected patients.

  • Proton pump inhibitors and cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer

    Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H, Nakamura T

    The Oncologist (Oxford University Press)   2024.02

    Research paper (scientific journal), Joint Work, Last author, Accepted,  ISSN  10837159

  • Drug repositioning study on the antiemetic efficacy of anamorelin for cisplatin-induced nausea and vomiting in rats

    Nishino H, Kawazoe H, Sekiguchi M, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T

    BPB Reports (The Pharmaceutical Society of Japan)  7 ( 1 ) 1 - 6 2024.01

    Joint Work, Last author, Accepted

  • Patient prognosis and prediction model for taking Kampo formulas in dysmenorrhea An observational study

    Maeda-Minami A, Kawamoto A, Yoshino T, Yokoyama Y, Suzuki S, Horiba Y, Nakamura T, Mimura M, Watanabe K

    Medicine (Wolters Kluwer)  102 ( 48 ) e36191 2023.12

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00257974

     View Summary

    Two representative Kampo formulas, keishibukuryogan and tokishakuyakusan, are frequently prescribed for patients with dysmenorrhea. We previously constructed a model that could predict which of these 2 formulas was most suitable, which is based on 4 subjective symptoms and 3 objective signs. To evaluate the prognosis of patients with dysmenorrhea using the established prediction model and assess the treatment outcomes between those treated in accordance with the prediction model and those who received various other treatments. In this retrospective, observational study, we included patients with menstrual pain who visited the Kampo Clinic at the Keio University Hospital for the first time between October 2014 and December 2020. These patients were monitored over a 90-day follow-up period. Participants were categorized into 2 groups: model-accordance and various-options. The progression of visual analogue scale (VAS) values was evaluated by determining the slopes from regression analysis between these 2 groups, with changes corroborated by the medical records. The study comprised 57 patients: 37 in the model-accordance group and 20 in the various-options group. Notably, the various-options group reported a significantly higher number of subjective symptoms (P = .03). The VAS value showed a decline, as indicated by the negative slope value of the regression line, across both groups - irrespective of their classification. There were no significant differences in the occurrence of adverse events between the 2 groups. The prognosis of patients with dysmenorrhea and the incidence of adverse events remained consistent, regardless of whether the treatment approach was in accordance with the prediction model or varied. Further studies are warranted to assess the prognosis when Kampo formulas are chosen based on the prediction model in the various-options population.

  • Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.

    Yokokawa T, Suzuki K, Tsuji D, Hosonaga M, Kobayashi K, Kawakami K, Kawazoe H, Nakamura T, Suzuki W, Sugisaki T, Aoyama T, Hashimoto K, Hatori M, Tomomatsu T, Inoue A, Azuma K, Asano M, Takano T, Ohno S, Yamaguchi M

    Cancer Medicine (Wiley)  12 ( 18 ) 18745 - 18754 2023.09

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    Background: Female sex and younger age are reported risk factors for chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV. Methods: This retrospective observational study analyzed data from consecutive patients who received their first cycle of perioperative anthracycline-based chemotherapy for breast cancer between January 2018 and June 2020. The endpoints were association between CINV (vomiting, ≥Grade 2 nausea, complete response [CR] failure) and menopause as well as the association between CINV and follicle-stimulating hormone [FSH]/estradiol [E2]. Results: Data for 639 patients were analyzed. Among these patients, 109 (17.1%) received olanzapine (four antiemetic combinations) and 530 (82.9%) did not (three antiemetic combinations). Premenopausal state (amenorrhea lasting ≥12 months) was significantly associated with ≥Grade 2 nausea and CR failure in univariate analysis but not in multivariate analysis. The premenopausal FSH/E2 group (defined by serum levels; FSH <40 mIU/mL and E2 ≥20 pg/mL) had a significantly higher rate of ≥Grade 2 nausea than the postmenopausal FSH/E2 group (FSH ≥40 mIU/mL and E2 <20 pg/mL) (48.8% vs. 18.8%, p = 0.023). Conclusions: Our results suggest that changes in FSH and E2 due to menopause may affect the severity of nausea and that FSH and E2 (especially FSH) levels might be useful indicators for CINV risk assessment.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 一般的な薬物と免疫チェックポイント阻害薬の体内動態~薬物は体内でどのような運命をたどって効果を発揮し体内から消失していくのか~

    鈴木小夜,中村智徳

    がん看護 (南江堂)  27 ( 2 ) 200 - 205 2022.02

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

  • 免疫チェックポイント阻害薬の体内動態と有効性/毒性との関係

    鈴木小夜,中村智徳

    がん看護 (南江堂)  27 ( 2 ) 206 - 212 2022.02

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

  • LC-MS/MSを用いた第二、三世代EGFR-TKI未変化体及び活性代謝物の血清中濃度同時測定法の構築と臨床に向けた検討

    石川恵海, 横山雄太, 千島陽奈, 国吉央城, 佐藤 到, 中谷直喜, 中島日出夫, 木村元範, 袴田 潤, 末廣直哉, 中田英夫, 池村辰之介, 平賀ゆい, 地引 綾, 河添 仁, 村松 博, 鈴木小夜, 中村智徳

    TDM研究 (日本TDM学会)  38 ( 2 ) 187 2021.05

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  0911-1026

  • Outcomes of clinical pharmacy research aimed at avoiding or reducing cancer chemotherapy-induced adverse reaction

    Hitoshi Kawazoe, Tomonori Nakamura

    医療薬学 (日本医療薬学会)  46 ( 9 ) 467 - 480 2020.09

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Recent studies related to side effects of Kampo medicines; Analysis of glycyrrhizic acid metabolites in patients suspected of psedoaldosteronism

    中村智徳、吉野鉄大、堀場裕子、渡辺賢治、三村 將、小川恵子、南澤 潔、並木隆雄、牧野利明

    医薬品相互作用研究 (医薬品相互作用研究会)  44 ( 2 ) 6 - 17 2020.06

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

display all >>

Presentations 【 Display / hide

  • 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築

    並木孝哉, 横山雄太, 枦 秀樹, 織田錬太郎, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳

    第44回日本臨床薬理学会学術総会, 

    2023.12

    Oral presentation (general)

  • 実習生の実務実習終了時における到達度評価を向上させる要因の検討

    石川春樹, 河添 仁, 岩田紘樹, 中村友紀, 地引 綾, 横山雄太, 小林典子, 鈴木小夜, 山浦克典, 中村智徳

    第33回日本医療薬学会年会, 

    2023.11

    Poster presentation

  • お薬手帳と比較した自記式質問紙による服薬情報の妥当性研究

    1. 矢嶋里菜, 松元美奈子, 原田成, 飯田美穂, 平田あや, 桑原和代, 宮川尚子, 中村智徳, 岡村智教, 武林 亨

    第82回日本公衆衛生学会総会 (つくば国際会議場) , 

    2023.10
    -
    2023.11

    Poster presentation, 日本公衆衛生学会

  • ESBL産生腸内細菌科細菌に対する血液透析患者の遊離形CMZ濃度を用いたPK/PDに基づく最適投与法の評価

    並木孝哉, 横山雄太, 枦 秀樹, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳

    第32回日本医療薬学会年会, 

    2023.09

    Oral presentation (general)

  • 効果的な薬物治療とヘルスサイエンス向上を目指した新規モバイル・ヘルス関連アプリケーション開発に向けた現状調査(2)

    斉藤将志, 福井一玄, 鈴木小夜, 横山雄太, 地引 綾, 河添 仁, 中村智徳

    第32回日本医療薬学会年会, 

    2023.09

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 和漢薬と西洋薬との併用における適正使用に向けた臨床薬理学的研究

    2013.04
    -
    2017.03

    日本学術振興会, Grant-in-Aid for Scientific Research, NAKAMURA, Tomonori, Research grant, Principal investigator

     View Summary

    実臨床での和漢薬と西洋薬との併用事例を検証し、東西医薬の併用に関する適正性の検証および有効性の科学的根拠と有害事象の発生を回避する指標の確立を目的とする。本研究期間内に、①当医療施設過去1~3 年間の全処方から西洋薬と和漢薬との併用事例を抽出し、その処方意図および有効性・安全性に関する事例をカルテ調査する。②無効例や有害事例での西洋薬の薬物動態に与える和漢薬の影響を精査する。③併用事例の有効性に関する実験薬理学的検証を行う。

  • アルコール含有抗がん薬投与時の自動車運転動作への影響の検討

    2013.04
    -
    2014.03

    全国共済農業協同組合連合会JA共済, 平成25年度JA共済交通事故医療研究助成, Research grant, Principal investigator

     View Summary

    抗がん薬の中にはアルコールを含有する製剤が存在し、単身乗用車で通院した際に自動車運転に影響を及ぼす可能性があり、帰宅前に迅速にアルコール血中濃度を測定し、自動車運転の可否を判断する方法を確立する必要がある。そこで本研究では、アルコール含有抗がん薬の投与を受けた患者の呼気中濃度と血中濃度との相関性を明らかにし、自動車運転動作への影響を検討する。

  • 実務実習における薬学生の薬学的介入に関する実態調査

    2013.04
    -
    2014.03

    Keio University, Keio Gijuku Academic Development Funds, NAKAMURA, Tomonori, Research grant, Principal investigator

     View Summary

    本学部5年次の病院・薬局実務実習を通じて経験した、薬物治療における未解決の臨床的課題に対する薬学的介入の有効性についての検証を目的として、以下の3点について検討した。
    ① OTC薬実習の実習内容に関する調査研究
    ② 実務実習での薬学生の服薬指導・コミュニケーションスキルの検証
    ③ 実務実習での薬学生の点眼薬服薬指導の有効性に関する検証

  • 生物学的製剤のリウマチ治療効果予測モデルの構築

    2014.04
    -
    2015.03

    公益財団法人 上原記念生命科学財団, 上原記念生命科学財団 平成25年度研究助成金, Research grant, Principal investigator

     View Summary

    関節リウマチ(RA)、全身性エリテマトーデス(SLE)等自己免疫疾患の薬物治療において大きな課題である「治療抵抗性」の克服に向けて、治療薬及びその代謝産物の体内動態と治療効果との相関性について検討することにより、薬動力学的解析に基づく適切な薬物療法支援システムの構築を目的とする。

  • 治療抵抗性リウマチ性疾患に対する個別化薬物治療に向けた臨床薬理学的研究

    2014.04
    -
    2015.03

    公益財団法人 薬学研究奨励財団, 第33回薬学研究奨励財団研究助成金, Research grant, Principal investigator

     View Summary

    全身性血管炎、全身性エリテマトーデスおよびリウマチ性疾患などの難治性自己免疫疾患の治療には主にステロイド剤や免疫抑制剤などが盛んに用いられている。しかし、これらの薬剤に対する抵抗性の発現により疾患制御が困難な症例が存在するが、その原因究明が十分に行われておらず、臨床上重要な課題となっている。そこで本研究ではステロイド応答性の個人差を規定する生体内因子を解明し、ステロイド抵抗性の改善策の確立を目的とする。

display all >>

Awards 【 Display / hide

  • 第8回日本薬学教育学会大会優秀発表賞

    牧山大輝, 松野昂樹, 小林聡太, 野々宮菜彌, 地引 綾, 横山雄太, 河添 仁, 津田壮一郎, 大谷壽一, 中村智徳, 鈴木小夜, 2023.08, 日本薬学教育学会, フィードバックと省察ワークシートによる介入が病院実務実習生のプロフェッショナリズム評価と省察能力に与えた影響

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第16回日本性差医学・医療学会学術集会優秀演題賞

    地引 綾, 村上紗恵子, 吉野鉄大, 堀場裕子, 横山雄太, 河添 仁, 鈴木小夜, 渡辺賢治, 中村智徳, 2023.02, 日本性差医学・医療学会, 更年期症状に対する漢方治療不応例の分析

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第32回日本医療薬学会年会 YIA(Young Investigator's Award)(社会人部門)

    並木孝哉, 横山雄太, 枦 秀樹, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳, 2022.09, 日本医療薬学会, ESBL産生腸内細菌科細菌に対する血液透析患者の遊離形CMZ濃度を用いたPK/PDに基づく最適投与法の評価

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第3回和漢医薬学会若手研究者フォーラム優秀発表賞

    仲道公輔, 地引 綾, 横山雄太, 河添 仁, 鈴木小夜, 吉野鉄大, 渡辺賢治, 秋山雅博, 金 倫基, 中村智徳, 2022.08, 和漢医薬学会, 抗肥満作用を有する漢方薬の薬効と腸内細菌叢構成の関連性の検討

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • ACCP 2022 in Nagoya Best Poster Presenter <Student>

    Kikuyama F, Suzuki S, Jibiki A, Yokoyama Y, Kawazoe H, Nakamura T, 2022.02, 21st Asian Conference on Clinical Pharmacy in Nagoya, Ingenol Mebutate Inhibits Proliferation of Pancreatic Cancer Cells at Lower Concentration than Other Established Antitumor Agents for Pancreatic Cancer

    Type of Award: Award from international society, conference, symposium, etc.

display all >>

 

Courses Taught 【 Display / hide

  • CLINICAL PHARMACY AND PHARMACOTHERAPY

    2023

  • CLINICAL PHARMACOLOGY

    2023

  • CASE STUDY PRACTICE

    2023

  • ADVANCED PRACTICAL TRAINING IN A HOSPITAL (ABROAD)

    2023

  • ADVANCED PRACTICAL TRAINING IN A HOSPITAL

    2023

display all >>

Courses Previously Taught 【 Display / hide

  • 早期体験学習(薬学科)

    Keio University

    2020.04
    -
    2021.03

    Spring Semester, Seminar, Within own faculty, 3h

    薬剤師の職能、病院・薬局見学、調剤体験、BLS実習、車いす・高齢者疑似体験

  • 実務実習事前学習

    Keio University

    2020.04
    -
    2021.03

    Autumn Semester, Laboratory work/practical work/exercise, Within own faculty, 164people

  • 薬局実務実習

    Keio University

    2018.04
    -
    2019.03

    Full academic year, Laboratory work/practical work/exercise, Within own faculty, 151people

  • 病院実務実習

    Keio University

    2018.04
    -
    2019.03

    Full academic year, Laboratory work/practical work/exercise, Within own faculty, 151people

  • D1病院・薬局に行く前にB

    Keio University

    2017.04
    -
    2018.03

    Autumn Semester, Lecture, Within own faculty, 164people

    医薬品の管理・供給、リスクマネージメント、処方解析

display all >>

Educational Activities and Special Notes 【 Display / hide

  • 早期臨床体験テキスト NEO薬学シリーズ12

    2017.03

    , Development of Textbook and Teaching Material

  • 現代医療における漢方薬 改訂第2版

    2016.01

    , Development of Textbook and Teaching Material

     View Details

    第7章 漢方薬の服薬指導

  • NEO薬学シリーズ3 Principal Pharmacotherapy

    2015.06

    , Development of Textbook and Teaching Material

     View Details

    第1部 身体の病的変化を知る 医薬品の安全性

  • 女性とくすりQ&A 患者に適した薬剤選択のために

    2008.09

    , Development of Textbook and Teaching Material

     View Details

    Ⅲ章 漢方、代替医療、サプリメント

  • ファーマコセラピー 病態生理からのアプローチ

    2007.08

    , Development of Textbook and Teaching Material

     View Details

    第51章 酸塩基平衡異常

 

Memberships in Academic Societies 【 Display / hide

  • 日本医薬品安全性学会, 

    2015
    -
    Present
  • American Society of Pharmacology & Experimental Therapeutics, 

    2011
    -
    Present
  • 日本薬物動態学会, 

    2009
    -
    Present
  • 日本臨床薬理学会, 

    2008
    -
    Present
  • 日本糖尿病学会, 

    2007
    -
    Present

display all >>

Committee Experiences 【 Display / hide

  • 2021.04
    -
    Present

    関東地区調整機構委員長, 薬学教育協議会

  • 2017.04
    -
    Present

    関東地区調整機構委員, 薬学教育協議会

  • 2017.01
    -
    2017.11

    第27回日本医療薬学会年会 実行委員, 日本医療薬学会

  • 2016.04
    -
    Present

    学術評議員, 日本薬理学会

  • 2016.04
    -
    2019.03

    学術雑誌編集委員, 日本薬学会

display all >>